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Abstract
Background: Autoimmune diseases are complex and have genetic and environmental
susceptibility factors. The objective was to test the genetic association of systemic lupus
erythematosus (SLE) and anti-neutrophil cytoplasmic antibody (ANCA) – associated systemic
vasculitis (AAV) with SNPs in the IL2RA region and to correlate genotype with serum levels of IL-
2RA.
Methods: Using a cohort of over 700 AAV patients, two SLE case-control studies and an SLE trio
collection (totalling over 1000 SLE patients), and a TaqMan genotyping approach, we tested 3 SNPs
in the IL2RA locus, rs11594656, rs2104286 & rs41295061, each with a prior association with
autoimmune disease; rs11594656 and rs41295061 with type 1 diabetes (T1D) and rs2104286 with
multiple sclerosis (MS) and T1D.
Results: We show that SLE is associated with rs11594656 (P = 3.87 × 10-7) and there is some
evidence of association of rs41295061 with AAV (P = 0.0122), which both have prior association
with T1D. rs2104286, an MS and T1D – associated SNP in the IL2RA locus, is not associated with
either SLE or AAV.
Conclusion: We have confirmed a previous suggestion that the IL2RA locus is associated with SLE
and showed some evidence of association with AAV. Soluble IL-2RA concentrations correlate with
rs11594656 genotype in quiescent disease in both AAV and SLE. Differential association of
autoimmune diseases and SNPs within the IL2RA locus suggests that the IL2RA pathway may prove
to play differing, as yet undefined, roles in each disease.
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Most autoimmune diseases are polygenic, with genetic
susceptibility being conferred by common variants at a
number of loci. It is evident that some susceptibility loci
are shared between autoimmune diseases. One locus that
is associated with several diseases including T1D, MS and
Graves' disease, is IL2RA [1-4].
The IL-2 pathway is critical for the maintenance of periph-
eral tolerance. Activated T cells and regulatory T cells
express IL-2RA, the high affinity IL-2 receptor (or CD25).
IL-2RA expression has also been reported on activated B
cells, activated monocytes, and NK cells [5]. IL-2 signal-
ling supports the division and survival of effector T cells,
plays a role in activation-induced cell death and is vital to
regulatory T cell homeostasis [6]. Its physiological role on
other IL-2RA expressing cell types, however, is unclear.
One human patient, homozygous for a 4 base pair exonic
deletion in IL2RA, lacking a functional IL-2RA demon-
strated increased susceptibility to viral, bacterial and fun-
gal infections, but unlike Il2ra-deficient mice did not
develop overt autoimmune disease [7]. Thus, the IL-2
pathway has a profound effect on the T cell immune
response, contributing to both activation and regulation
depending on the immunological context.
In T1D, two disease-associated SNPs [rs11594656 and
rs41295061] are required to explain association with this
region of chromosome 10p15, indicating that there are
multiple functional alleles of the IL2RA locus, presumably
altering expression of the receptor [1,2]. In addition, asso-
ciations have been established with multiple sclerosis
(MS) [rs2104286] [3], and suggested with Graves' disease
[4]. The SNP, rs2104286, has also been associated recently
with T1D, representing a third independent effect for the
IL2RA region in this autoimmune disease [8]. In systemic
lupus erythematosus (SLE), SNPs without any prior
autoimmune associations [rs7072793, rs4147539,
rs7090530 and rs12251307] were examined in a candi-
date gene analysis of IL2RA, providing weak evidence for
association [9]. Soluble IL-2RA (sIL-2RA) is shed from
human T cells following in vitro activation in response to
a variety of polyclonal stimuli [5]. Significantly elevated
serum sIL-2RA has been described in infection, malig-
nancy and in autoimmune disease, including T1D, rheu-
matoid arthritis, SLE and Wegener's granulomatosis
[5,10], although the functional implications of this
remain unclear. Genotype at rs11594656 and rs41295061
[2], and most recently with rs2104286 [8], has been
shown to correlate with serum sIL-2RA concentrations.
We therefore genotyped autoimmune disease-prone vari-
ants of the IL2RA region (rs11594656, rs41595061 and
rs2104286) in two distinct autoimmune diseases associ-
ated with soluble IL-2RA elevation, using three independ-
ent SLE cohorts and one AAV cohort. SLE is a polygenic
multi-system disease characterised by immune complex
formation and deposition, frequently associated with
anti-dsDNA antibodies and complement dysregulation.
The clinical features vary between patients, both in sever-
ity and system involvement, and include joint, skin, renal
and neurological manifestations. AAV can be divided into
three clinical syndromes (Wegener's granulomatosis,
microscopic polyangiitis and Churg-Strauss syndrome).
All are characterised by inflammation of medium to small
calibre blood vessels, and the presence of anti-neutrophil
cytoplasmic antibody (ANCA). The clinical presentation
of AAV is variable between patients. Severe manifestations
include acute glomerulonephritis and granulomatous
inflammation of the upper and lower respiratory tract. We
also assessed serum titres of sIL-2RA in both diseases.
Methods
AAV
The AAV cohort (n = 744) comprises subjects from four
sources, all meeting the Chapel Hill diagnostic criteria
[11]:
1. The MRC/Kidney Research UK National DNA Bank for
Glomerulonephritis (KRUK-AAV). Individuals were
between the ages of 18 and 70 years, were ANCA seropos-
itive, and had biopsy-proven necrotizing glomerulone-
phritis.
2. The UK vasculitis cohort 2 was recruited from 9 centres
in the UK and comprised patients seropositive for ANCA
and/or with histological evidence of small vessel vasculi-
tis.
3. Patients recruited from the University of Birmingham.
All individuals were ANCA seropositive with firm clinical
and/or histological evidence of vasculitis.
4. The Lupus and Vasculitis Service, Addenbrooke's Hos-
pital, Cambridge. All individuals were ANCA seropositive
with firm clinical and/or histological evidence of vasculi-
tis.
SLE
The KRUK-SLE cohort (n = 220) was obtained from the
MRC/Kidney Research UK National DNA Bank for
Glomerulonephritis (KRUK) and the Lupus and Vasculitis
Service, Addenbrooke's Hospital, Cambridge. All individ-
uals were between the ages of 18 and 50 years with a def-
inite diagnosis of lupus nephritis based on biopsy and on
the clinical and serological features defined by the Ameri-
can College of Rheumatology (ACR) [12]. The Imperial
case-control cohort comprised 480 SLE patients and there
were 471 trios in the Imperial family cohort (ie 471
affected sons/daughters, 942 parents) [13]. Both Imperial
cohorts used the ACR defined clinical and serological fea-Page 2 of 7
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inclusion criterion of biopsy-proven renal involvement, it
was analysed separately from the Imperial case-control
cohort.
Genotyping was performed using TaqMan genotyping kits
(Applied Biosystems) for each SNP, with fluorescence
data captured using an ABI 7900HT (Applied Biosystems)
after 40 cycles of PCR.
Assessment of disease activity
Birmingham Vasculitis Activity Scores (BVAS) were calcu-
lated for AAV patients seen by the Lupus and Vasculitis
Service at Addenbrooke's hospital. BVAS assesses both
constitutional and organ-specific symptoms, determining
whether they are new or pre-existing [14]. British Isles
Lupus Assessment Group (BILAG) scores were used to
assess disease activity in SLE patients seen by the Lupus
and Vasculitis Service at Addenbrooke's hospital. BILAG
scores assess 9 different organ systems based upon a phy-
sician's intention to treat [15]. A flare was defined when
three criteria were met: 1. Worsening disease activity
scores (at least 1 major or 3 minor BVAS criteria for AAV;
a new BILAG score A or B in any system for SLE), 2. clinical
impression of active disease and 3. an increase in immu-
nosuppressive treatment.
Controls
Control genotypes for 9115 individuals from the British
1958 Birth Cohort and UK Blood Service were obtained
from the Juvenile Diabetes Research Foundation/Well-
come Trust Diabetes and Inflammation Laboratory [16].
This cohort is an expansion of a dataset previously shown
to be appropriate for us as UK-wide controls [17]. The
SLE and AAV are associated with different SNPs in the IL2RA regionFigure 1
SLE and AAV are associated with different SNPs in the IL2RA region. The genomic context of rs2104286, 
rs41295061 and rs11594656 is shown, using the GBrowse implementation in T1DBase http://www.t1dbase.org. All are non-
coding SNPs. Negative decimal logarithms of P values (χ2 test; 1 degree of freedom) from each cohort from SLE and AAV are 
plotted for rs41295061 and rs11594656 but not for rs2104286, as an association of this MS-associated SNP was not detected 
with SLE or AAV (table 1). Open circles represent the KRUK case-control cohort; filled circles the Imperial case-control 
cohort and open squares the Imperial family trios (P value from TDT). The filled square represents the combined P value for 
rs11594656 in SLE. Crosses are used for the AAV cohort. The dashed lines correspond to P = 0.05.
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ing study following all births in England, Scotland and
Wales in one week in 1958 http://
www.b58cgene.sgul.ac.uk. For the SLE analysis, controls
were split into two groups and one group used as controls
for each case cohort: n = 4534 controls for the KRUK
cohort and n = 4581 for the Imperial cohort. Some of
these control individuals were used in the earlier T1D
studies [1,2].
ELISA
Serum soluble IL-2RA was measured in triplicate using an
ELISA, according to the manufacturer's instructions (R&D
Systems). Serum from both AAV and SLE patients was col-
lected at presentation with a 'flare' (time 0, see Assessment
of disease activity section) and three months later (3
months) by the Lupus and Vasculitis Service, Adden-
brooke's Hospital, Cambridge.
Statistical analysis
Statistical analysis was performed using Prism (Graph-
Pad), and R http://www.r-project.org. Case control analy-
ses were performed using χ2 tests for significance on 2 × 2
contingency tables. Odds ratios and 95% confidence
intervals were calculated from the same 2 × 2 tables. The
Imperial trio data was analysed using the transmission
disequilibrium test (TDT). ELISA data were tested for sig-
nificance using linear regression modelling or the Mann-
Whitney test, as indicated in the figure legends.
This study was approved by the Cambridge Local Research
Ethics Committee and by the Oversight Committee of the
KRUK DNA Bank.
Results
In all three of our SLE cohorts, rs11594656 was found to
be significantly associated with disease (protective minor
allele, as seen in T1D), combined P = 3.87 × 10-7 (KRUK
case control P = 1 × 10-4, Imperial case control P = 0.0221
and Imperial family trio TDT P = 2.8 × 10-3) (Figure 1 and
Table 1). Neither of the other two SNPs were associated
with SLE (Figure 1 and Table 1). In AAV, in contrast, some
evidence for an association was found with rs41295061
(P = 0.0122; minor allele odds ratio = 0.7739; 95% OR CI
0.6330 – 0.9461). The minor allele is protective as in T1D.
However, neither rs2104286 or rs11594656 showed any
Table 1: Genotype data at rs11594656, rs41295061 and rs2104286 for SLE and AAV
SLE AAV
KRUK cases Imperial cases Imperial trios
rs11594656 T>A
Genotyped cases 208 441 481 670
TT, TA, AA 148, 52, 8 276, 145, 20 382, 252, 36
Genotyped controls 4401 4449 310 * 8850
TT, TA, AA 2486, 1655, 260 2542, 1640, 267 5028, 3295, 527
MAF in cases 0.16 0.20 - 0.24
P value (1 d.f. test) 1 × 10-4 0.0221 2.8 × 10-3 0.7481
OR for minor allele 0.595 0.82 - 1.02
95% CI for OR 0.4570 – 0.7756 0.6931 – 0.9723 - 0.8972 – 1.163
rs41295061 C>A
Genotyped cases 208 421 471 675
CC, CA, AA 172, 33, 3 330, 80, 11 569, 102, 4
Genotyped controls 4438 4498 137 * 8936
CC, CA, AA 3603, 790, 45 3603, 832, 63 7206, 1622, 108
MAF in cases 0.09 0.12 - 0.08
P value (1 d.f. test) 0.7187 0.1899 0.2000 0.0122
OR for minor allele 0.94 1.154 - 0.7739
95% CI for OR 0.6710 – 1.317 0.9307 – 1.438 - 0.6330 – 0.9461
rs2104286 A>G
Genotyped cases 198 436 471 380
AA, AG, GG 113, 74, 11 234, 158, 44 207, 148, 25
Genotyped controls 3475 3529 353 * 7004
AA, AG, GG 1823, 1403, 249 1825, 1452, 252 3648, 2855, 501
MAF in cases 0.24 0.28 - 0.26
P value (1 d.f. test) 0.1760 0.7568 0.558 0.3727
OR for minor allele 1.177 0.9756 - 1.078
95% CI for OR 0.9294 – 1.490 0.8343 – 1.141 - 0.9133 – 1.273
MAF minor allele frequency; OR odds ratio; CI confidence interval; * informative transmissions. Genotype frequencies are shown for the case 
control cohorts.Page 4 of 7
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Serum soluble IL-2RA in SLE and AAV and its relationship with disease activity and genotype at rs11594656Fig re 2
Serum soluble IL-2RA in SLE and AAV and its relationship with disease activity and genotype at rs11594656. 
(a) A comparison of SLE and AAV soluble IL-2RA (sIL-2RA) at time 0 and 3 months compared with controls, as assessed by 
ELISA. Each dot represents a patient. (b, c) Correlation between disease activity and sIL-2RA. (BILAG for SLE; BVAS for AAV; 
see supplementary information). r2 and P values from linear regression modelling are shown. (d, e) sIL-2RA levels stratified by 
genotype at rs11594656 at both time 0 and 3 months for SLE (d) and AAV (e). P values for panels (a), (d) & (e) were generated 
using the Mann-Whitney test.
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power, we can detect effect sizes larger than 1.25 for
rs11594656 in AAV and 1.4 for rs41295061 in SLE, across
all the SLE cases and controls.
In both SLE and AAV, sIL-2RA concentrations were signif-
icantly higher than controls (Figure 2a). In SLE, disease
activity as assessed by BILAG score did not show a signifi-
cant correlation with sIL-2RA concentrations (Figure 2b),
despite previous reports of a correlation between sIL-2RA
concentrations and disease activity [5]. However, in AAV,
disease activity as assessed by BVAS showed a positive cor-
relation with sIL-2RA concentration (Figure 2c, [10]).
Three months after commencement of treatment, when
both diseases were considerably less active (mean BILAG
decreased from 16.1 to 4.7 and mean BVAS from 13.9 to
4.4), sIL-2RA concentrations correlated with the SLE asso-
ciated rs11594656 genotype (Figures 2d &2e). In active
AAV this correlation no longer held true (figure 2e).
Discussion
We have shown a novel IL2RA association with AAV and
confirm the IL2RA locus association with SLE. This brings
the number of autoimmune diseases associated with this
gene to five, the others being T1D, MS and Graves' disease
[1-4]. An association of SLE with IL2RA (rs7072793, P =
0.01) was generated by candidate gene re-analysis of
genome-wide association data from 720 female patients
[9]. The present study uses 1130 SLE genotypes, of mixed
gender, in three independent cohorts, and demonstrates a
strong association with the IL2RA region (rs11594656, P
= 3.87 × 10-7). Owing to strong co-segregation of these
disorders in cases and families, susceptibility loci can be
shared across different autoimmune diseases. Several
examples at the gene-specific level are known, including
CTLA-4 [18] and PTPN22 [19]. Our study underlines that
this sharing can occur at the single gene level for IL2RA for
T1D and SLE, two diseases in which co-segregation is less
well recognised.
Our findings demonstrate that the association between
IL2RA and autoimmune disease is not a simple one. SLE
is associated with rs11594656, but not rs41295061 and in
AAV there is some evidence for an association with
rs41295061 but not with rs11594656. Moreover, in T1D,
all three SNPs are associated with disease, but the strength
of association varies with each (rs41295061, P = 6.43 ×
10-25; rs2104286, P = 1.27 × 10-13; rs11594656, P = 3.37 ×
10-6) [2,8]. In MS, whilst rs2104286 is associated with dis-
ease [3], rs11594656 or rs41295061 are not (rs11594656,
P = 0.293; rs41295061, P = 0.625) [8].
There are differences at the functional level as well, with
rs11594656 genotype correlated with sIL-2RA levels in
both SLE and AAV despite only having genetic association
with SLE. This correlation is present in both SLE and AAV
three months following disease flare, but absent at the
time of flare itself, perhaps because local inflammatory
mechanisms provide a major contribution to sIL-2RA,
overriding the influence of genotype. Thus the degree of
autoimmune disease activity needs to be taken into
account in studies attempting to correlate genotype with
markers such as sIL-2RA.
There is precedent for such contrasting functional and
genetic associations between SLE and AAV. FcγRIIIb, a
neutrophil-specific low affinity activatory Fc receptor, has
two allotypic variants, which have a significant effect on
the affinity of the receptor for IgG. One of these,
FCGR3B*NA1, is associated with SLE, and the other,
FCGR3B*NA2, with AAV [20,21]. Moreover, copy number
at FCGR3B is associated with expression and function of
the receptor [22], and low copy number is associated with
SLE [23] but not with AAV ([22] & data not shown). The
association of a single gene with different diseases indi-
cates the importance in disease of the biological pathway
subserved by that gene, but it does not imply that defects
in the gene lead to a similar functional perturbation in
each case. Thus the same gene, IL2RA, is associated with
both SLE and AAV, but may play quite distinct roles in
these diseases.
Conclusion
We confirm the association of the IL2RA locus with SLE,
by genotyping rs11594656 across three independent
cohorts, using two different study designs. We report evi-
dence for a novel association of the IL2RA locus with AAV.
The MS-associated SNP, rs2104286, is not associated with
either disease in our cohorts. Soluble IL-2RA concentra-
tions were elevated in SLE and AAV. After three months of
treatment, soluble IL-2RA concentrations in both diseases
correlated with the SLE associated rs11594656 genotype.
The contrasting genetic and functional associations found
between SLE and AAV and the IL2RA locus presumably
reflect differences in disease pathogenesis.
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